


In the Claims

Please amend the claims as follows:

Claim 1 (Previously Amended) A compound of Formula I



or a pharmaceutically acceptable salt of said compound;

wherein R_1 is a) $-(C_1-C_6)$ alkyl optionally substituted with $-CF_3$, b) $-C\equiv C-CH_3$, c) $-C\equiv C-Cl$, d) $-C\equiv C-CF_3$, e) $-CH_2O(C_1-C_4)$ alkyl optionally substituted with $-CF_3$ or f) $-CF_3$;

R_2 is a) $-(C_1-C_5)$ alkyl, b) $-(C_2-C_5)$ alkenyl or c) -phenyl optionally substituted with one of the following: $-OH$, $-NR_9-C(O)-(C_2-C_4)$ alkyl, $-CN$, $-Z$ -het, $-O-(C_1-C_3)$ alkyl- $C(O)-NR_9R_{10}$, $-NR_9-Z-C(O)-NR_9R_{10}$, $-Z-NR_9-SO_2-R_{10}$, $-NR_9-SO_2$ -het, $-O-C(O)-(C_1-C_4)$ alkyl or $-O-SO_2-(C_1-C_4)$ alkyl;

Z for each occurrence is independently $-(C_0-C_4)$ alkyl;

R_3 is a) -hydrogen, b) $-(C_1-C_6)$ alkyl optionally substituted with one to three halo, c) $-(C_2-C_6)$ alkenyl or d) $-(C_2-C_6)$ alkynyl optionally substituted with one to three halo;

R_4 is a) -hydrogen, or b) $-(C_2-C_5)$ alkyl- NR_5R_6 ;

R_5 and R_6 are each independently a) hydrogen or b) $-(C_1-C_3)$ alkyl;

het is an optionally substituted 5-, 6- or 7-membered saturated, partially saturated or unsaturated heterocyclic ring containing from 1 to 3 heteroatoms selected from the group consisting of nitrogen, oxygen and sulfur; and including any bicyclic group in which any of the above heterocyclic rings is fused to a benzene ring or another heterocyclic ring; and optionally

substituted with one to four R_7 ; provided that het is other than pyridinyl, imidazolyl or tetrazolyl;

R_7 is a) $-(C_1-C_6)\text{alkyl}$ optionally substituted with one to three R_8 , b) $-Z-NR_9R_{10}$ or c) $-Z-C(O)-NR_9R_{10}$;

R_8 for each occurrence is independently a) halo, b) $-OH$, c) oxo or d) $-O(C_1-C_6)\text{alkyl}$;

R_9 and R_{10} for each occurrence are independently a) $-H$ or b) $-(C_1-C_3)\text{alkyl}$; or R_9 and R_{10} are taken together with N to form het;


provided that:

1) when R_1 is $-C\equiv C-CH_3$, R_2 is phenyl and R_3 is hydrogen, then R_4 is other than $-(CH_2)_2-N(CH_3)_2$, or $-(CH_2)_3-N(CH_3)_2$, $-(CH_2)_2$ -pyrrolidinyl optionally substituted with methyl, $-(CH_2)_3$ -pyrrolidinyl or $-(CH_2)_2$ -morpholinyl;

2) when R_1 is $-C\equiv C-CH_3$, R_2 is propyl and R_3 is hydrogen, then R_4 is other than $-(CH_2)_2-N(CH_3)_2$; and

3) when R_1 is $-C\equiv C-CH_3$, R_2 is butyl and R_3 is hydrogen, then R_4 is other than $-(CH_2)_2-N(CH_3)_2$.

Claim 2 (Previously Amended) A compound of claim 1 of Formula II



II

or a pharmaceutically acceptable salt of said compound;

wherein R_1 is a) $-(C_1-C_6)\text{alkyl}$ optionally substituted with $-CF_3$, b) $-C\equiv C-CH_3$, c) $-CF_3$ or d) $-CH_2O(C_2-C_4)\text{alkyl}$.

Claim 3 (Original) A compound of claim 2 wherein R_1 is a) $-CH_2CH_2CH_3$, b) $-C\equiv C-CH_3$ or c) $-CF_3$.

Claim 4 (Original) A compound of claim 3

wherein R_3 is a) hydrogen, b) methyl, c) ethyl, d) propyl or e) isopropyl;

R_4 is $-(C_2-C_3)\text{alkyl}-NR_5R_6$;

R_5 and R_6 are each independently a) methyl, b) ethyl, c) propyl or d) isopropyl.

Claim 5 (Original) A compound of claim 4

wherein R_3 is a) methyl, b) ethyl, c) propyl or d) isopropyl;

R_4 is $-(C_2-C_3)\text{alkyl}-NR_5R_6$;

R_5 and R_6 are each independently a) methyl, b) ethyl, c) propyl or d) isopropyl.

Claim 6 (Original) A compound of claim 5

wherein R_3 is a) methyl or b) ethyl;

R_4 is $-(C_2-C_3)\text{alkyl}-NR_5R_6$;

R_5 and R_6 are each methyl.

Claims 7-11 (Previously Canceled)

Claim 12 (Original) A compound of claim 1

wherein R_1 is a) $-\text{CH}_2\text{CH}_2\text{CH}_3$, b) $-\text{C}\equiv\text{C}-\text{CH}_3$ or c) $-\text{CF}_3$;

R_2 is a) $-(C_1-C_5)\text{alkyl}$ or b) $-(C_2-C_5)\text{alkenyl}$;

R_3 is a) hydrogen, b) methyl, c) ethyl, d) propyl or e) isopropyl;

R_4 is $-(C_2-C_3)\text{alkyl}-NR_5R_6$;

R_5 and R_6 are each independently a) methyl, b) ethyl, c) propyl or d) isopropyl.

Claim 13 (Original) A compound of claim 12

wherein R_2 is a) methyl, b) ethyl, c) propyl, d) ethenyl, e) propenyl or f) butenyl;

R_3 is a) hydrogen, b) methyl or c) ethyl,

R_5 and R_6 are each independently a) methyl or b) ethyl.

Claims 14-17 (Previously Canceled)

Claim 18 (Original) A compound of claim 1 wherein in Formula I $-\text{CH}_2-$
 R_2 is ethenyl or ethynyl.

Claim 19 (Original) A compound of claim 4 selected from the group consisting of:

carbamic acid, [2-(dimethylamino)ethyl]-, (4b*S*,7*R*,8a*R*)-
4b,5,6,7,8,8a,9,10-octahydro-7-hydroxy-4b-(phenylmethyl)-7-(trifluoromethyl)-
2-phenanthrenyl ester;

carbamic acid, [3-(dimethylamino)propyl]-, (4b*S*,7*R*,8a*R*)-
4b,5,6,7,8,8a,9,10-octahydro-7-hydroxy-4b-(phenylmethyl)-7-(trifluoromethyl)-
2-phenanthrenyl ester; and

carbamic acid, [3-(diethylamino)propyl]-, (4b*S*,7*R*,8a*R*)-
4b,5,6,7,8,8a,9,10-octahydro-7-hydroxy-4b-(phenylmethyl)-7-(trifluoromethyl)-
2-phenanthrenyl ester.

Claim 20 (Original) A compound of claim 6 selected from the group
consisting of:

carbamic acid, [2-(dimethylamino)ethyl]methyl-, (4b*S*,7*R*,8a*R*)-
4b,5,6,7,8,8a,9,10-octahydro-7-hydroxy-4b-(phenylmethyl)-7-(trifluoromethyl)-
2-phenanthrenyl ester;

carbamic acid, [2-(dimethylamino)ethyl]methyl-, (4b*S*,7*R*,8a*R*)-
4b,5,6,7,8,8a,9,10-octahydro-7-hydroxy-4b-(phenylmethyl)-7-propyl-2-
phenanthrenyl ester;

carbamic acid, [3-(dimethylamino)propyl]ethyl-, (4b*S*,7*R*,8a*R*)-
4b,5,6,7,8,8a,9,10-octahydro-7-hydroxy-4b-(phenylmethyl)-7-(trifluoromethyl)-
2-phenanthrenyl ester; and

carbamic acid, [2-(dimethylamino)ethyl]ethyl-, (4b*S*,7*R*,8a*R*)-
4b,5,6,7,8,8a,9,10-octahydro-7-hydroxy-4b-(phenylmethyl)-7-(trifluoromethyl)-
2-phenanthrenyl ester.

Claim 21-23 (Previously Canceled)

Claim 24 (Original) A compound of claim 13 selected from the group
consisting of:

carbamic acid, (3-dimethylaminopropyl)methyl-, (4b*S*, 7*R*, 8a*R*)-
4b,5,6,7,8,8a,9,10-octahydro-4b-ethyl-7-hydroxy-7-prop-1-ynyl-phenanthren-
2-yl ester;

carbamic acid, (2-dimethylaminoethyl)methyl-, (4b*S*, 7*R*, 8a*R*)-
4b,5,6,7,8,8a,9,10-octahydro-4b-ethyl-7-hydroxy-7-prop-1-ynyl-phenanthren-
2-yl ester;

carbamic acid, (2-dimethylaminoethyl)ethyl-, (4bS, 7R, 8aR)-
4b,5,6,7,8,8a,9,10-octahydro-4b-ethyl-7-hydroxy-7-prop-1-ynyl-phenanthren-
2-yl ester; and

carbamic acid, (2-dimethylaminoethyl)-, (4bS, 7R, 8aR)-
4b,5,6,7,8,8a,9,10-octahydro-4b-ethyl-7-hydroxy-7-prop-1-ynyl-phenanthren-
2-yl ester.

Claims 25-26 (Previously canceled)

Claim 27 (Newly amended) A method for the treatment of a
glucocorticoid receptor-mediated disease or condition which is selected from
the group consisting of obesity, diabetes, depression, anxiety and
neurodegeneration in a mammal, which comprises administering to the
mammal a therapeutically effective amount of a compound of claim 1, or a
pharmaceutically acceptable salt of said compound.

Claim 28 (Previously canceled)

Claim 29 (Previously amended) The method of claim 27 wherein
the condition is obesity.

Claims 30-41 (Previously canceled)